Continued Survival Benefits Observed With Encorafenib/Binimetinib Combo in Advanced Melanoma

Wayne Kuznar
Published: Wednesday, Jun 12, 2019
Helen J. Gogas, MD, PhD

Helen J. Gogas, MD, PhD

Updated results from the phase III COLUMBUS trial show continued prolonged progression-free and overall survival (OS) with the combination of encorafenib (Braftovi) and binimetinib (Mektovi) compared with BRAF inhibition alone in patients with advanced/metastatic BRAF V600-mutant melanoma.

In part 1 of the international COLUMBUS study, 577 patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma were randomized 1:1:1 to receive encorafenib 450 mg twice daily in combination with binimetinib 45 mg twice daily (n = 192), encorafenib alone at 300 mg daily (n = 194), or vemurafenib 960 mg twice daily (n = 191).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication